DocMorris Stock

DocMorris EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of DocMorris (DOCM.SW) as of Aug 14, 2026 is -2.35. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -1.90 — a change of 23.65% (lower).

EV/EBIT

-2.35

YoY

23.65%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of DocMorris is 2026 -2.35 . EV/EBIT (Enterprise Value to EBIT) of DocMorris was 2025 -1.90 . It decreases by 23.65% lower compared to the previous year.

The DocMorris EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
-21.02 base
Jan 1, 2020
-23.77 base
Jan 1, 2021
-11.37 base
Jan 1, 2022
7.13 base
Jan 1, 2023
-11.46 base
Jan 1, 2024
-2.27 base
Jan 1, 2025
-3.64 base
Jan 1, 2026 (e)
-3.75 base
YEARPRICE-TO-EBIT
2026 est -3.75
2025 -3.64
2024 -2.27
2023 -11.46
2022 7.13
2021 -11.37
2020 -23.77
2019 -21.02
2018 -15.91
2017 -23.92
2016 -
2015 -
2014 -
2013 -
2012 -
2011 -
2010 -
Access this data via the Eulerpool API

DocMorris Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides DocMorris's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates DocMorris's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots DocMorris's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if DocMorris grows earnings faster than its peers.

DocMorris Stock analysis

What does DocMorris do? The Zur Rose Group AG is a Swiss company that specializes in online trading of medications and health products. The company was founded in 1993 in Steckborn and initially focused on the mail order of homeopathic medicines. In 1997, the online shop www.zurrose.de was opened and the company began to expand its distribution to non-homeopathic medicines. The business model of the Zur Rose Group AG is based on a three-pillar model, encompassing e-commerce, wholesale, and healthcare. In the e-commerce sector, the company operates online pharmacies in various countries including Germany, France, Austria, the Netherlands, and Switzerland. In the wholesale sector, the company supplies pharmacies and hospitals with medicines and medical products. In the healthcare sector, the company offers various services in healthcare, from the production of medicines to the processing of prescriptions. The Zur Rose Group AG offers a wide range of products and services including prescription and over-the-counter medications, natural remedies, cosmetic products, dietary supplements, and medical devices. The company aims to provide its customers with a comprehensive selection of high-quality products and works closely with its suppliers to ensure that all products meet the highest quality standards. In the e-commerce sector, the company operates various online pharmacies, including Zur Rose Apotheke in Germany, Zur Rose Apotheke in Austria, and Doctipharma in France. These online pharmacies offer a wide range of medications and health products that can be ordered online and conveniently delivered to customers' homes. The online pharmacies are open 24/7, allowing customers to quickly and easily order their needed medications. In the wholesale sector, the company offers a wide range of pharmaceutical products and medical devices to pharmacies and hospitals. The company works closely with its suppliers to ensure that all products meet the highest quality standards. Additionally, the company also provides a fast and reliable delivery service to ensure that its customers are always provided with the needed medications and medical products. In the healthcare sector, the company offers various services in healthcare, including digitalization solutions for pharmacies, manufacturing of medications, and processing of prescriptions. The company works closely with its customers to offer tailored solutions that meet their individual requirements. Over the years, the Zur Rose Group AG has become a leading provider in the online trading of medications and health products. The company has distinguished itself through its wide product range, fast and reliable delivery service, and excellent customer service. Additionally, the company has also invested in the development of new technologies to ensure that it can always offer its customers the best products and services. Overall, the Zur Rose Group AG is an innovative company built on a long history in healthcare. The company strives to offer its customers a wide range of high-quality products and services and has established itself as a leading provider in the online trading of medications and health products. DocMorris is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DocMorris stock

EV/EBIT (Enterprise Value to EBIT) of DocMorris is -2.35 in 2026.

EV/EBIT (Enterprise Value to EBIT) of DocMorris changed from -1.90 to -2.35, representing a 23.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) DocMorris since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s DocMorris with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — DocMorris

All Key Metrics — DocMorris